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Abstract: In several human diseases, such as cancer and neurodegenerative diseases, the levels of
reactive oxygen species (ROS), produced mainly by mitochondrial oxidative phosphorylation, is
increased. In cancer cells, the increase of ROS production has been associated with mtDNA mutations
that, in turn, seem to be functional in the alterations of the bioenergetics and the biosynthetic
state of cancer cells. Moreover, ROS overproduction can enhance the peroxidation of fatty acids in
mitochondrial membranes. In particular, the peroxidation of mitochondrial phospholipid cardiolipin
leads to the formation of reactive aldehydes, such as 4-hydroxynonenal (HNE) and malondialdehyde
(MDA), which are able to react with proteins and DNA. Covalent modifications of mitochondrial
proteins by the products of lipid peroxidation (LPO) in the course of oxidative cell stress are
involved in the mitochondrial dysfunctions observed in cancer and neurodegenerative diseases. Such
modifications appear to affect negatively mitochondrial integrity and function, in particular energy
metabolism, adenosine triphosphate (ATP) production, antioxidant defenses and stress responses. In
neurodegenerative diseases, indirect confirmation for the pathogenetic relevance of LPO-dependent
modifications of mitochondrial proteins comes from the disease phenotypes associated with their
genetic alterations.
Keywords: mitochondria; cancer; neurodegenerative diseases; fatty acid oxidation;
lipoperoxidation products
1. Introduction
It is noteworthy that cancer cells exhibit several metabolic alterations, which include increased
fatty acid synthesis and glutamine metabolism, and dependence on aerobic glycolysis for energy
needs [1,2], collectively referred to as the “Warburg effect” [3]. Recent evidence indicates that the
Warburg effect could be a universal phenomenon in normal proliferating cells, such as mammalian
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early embryonic cells, stem cells, primary spermatocytes, and even in virus-infected cells, thus the
study of the Warburg effect in these conditions could represent a breakthrough point, helping to
elucidate the Warburg effect in cancer cells [4]. The importance of the Warburg effect in cancer has
been outlined by Hanahan and Weinberg, who included the reprogramming of energy metabolism in
the emerging hallmarks of cancer [5]. Among the different mitochondrial pathways involved in energy
metabolism, β-oxidation of fatty acid is of particular interest because its inhibition has been suggested
as a potential target to reduce tumor growth [6,7]. On the other hand, due to their role in adenosine
triphosphate (ATP) production through oxidative phosphorylation (OXPHOS), mitochondria are the
main intracellular producers of reactive oxygen species (ROS), which, in turn, can react with lipids
and induce lipid peroxidation (LPO). Peroxidation of polyunsaturated fatty acids (PUFAs) generates
an array of primary products, among which 4-hydroxynonenal (HNE) is one of the best-studied active
lipid electrophiles. This aldehyde, by reacting with mitochondrial proteins, may contribute to altered
mitochondrial functions not only in cancer cells, but also in other diseases, in which oxidative stress is
increased, such as chronic inflammations and neurodegenerative diseases [8,9]. Moreover, both ROS
and reactive aldehydes can interact with mtDNA to produce mtDNA mutations and, as a consequence,
alterations in encoded proteins that are crucial for mitochondrial functions [10–12].
In this review, we discuss the recent findings in mitochondrial dysfunctions in cancer cells related
to fatty acid composition, ROS production, LPO, and the role played by mitochondrial lipoperoxidation
products in cancer and neurodegenerative disorders.
2. Mitochondrial Dysfunction in Cancer
2.1. Aerobic Glycolysis and Oxidative Phosphorylation
One well-known example of mitochondrial dysfunction in cancer cells is the cancer-associated
metabolic switch towards aerobic glycolysis, known as the Warburg effect [3], which enables cancer
cells to direct the utilization of glucose supplies towards the biosynthesis of macromolecules, thus
supporting their rapid growth. In order to meet their energy needs, normal cells oxidize glucose via the
mitochondrial tricarboxylic acid cycle (TCA), also known as Krebs cycle, to generate ~30 ATP molecules
per glucose molecule. By contrast, cancer cells rely heavily on glycolysis to generate two ATPs per
glucose molecule in the cytoplasm. Hence, cancer cells, such as those of gliomas, meningiomas and
sarcomas, upregulate glucose transporters to increase glucose uptake into the cell, in order to meet
their energy needs [13,14]. Moreover, mutations of mitochondrial enzymes (e.g., fumarate hydratase,
succinate dehydrogenase and isocitrate dehydrogenase) and other key components of glycolysis and
Krebs cycle are a general feature of cancer cells, leading to a reduced production of pyruvate via
glycolysis and an increased flux towards biosynthetic and NADPH-producing pathways, such as
serine biosynthesis and the pentose phosphate pathway [12].
It has been demonstrated that the Warburg effect is also present in normal, highly proliferating
cells, in which the increase of aerobic glycolysis, associated with a reduced OXPHOS activity, could
be a protective strategy against ROS [15]. Indeed, in normal cells, aerobic glycolysis attenuates
OXPHOS, which is the major source of mitochondrial ROS. On the contrary, in cancer cells, despite the
reduction of OXPHOS capacity [12], the level of ROS produced, mainly by the electron transfer sites,
is generally increased [16] and has been associated with mtDNA mutations [4]. Overall, OXPHOS
activity, even though reduced, is not suppressed in tumor cells, and mtDNA mutations seem to be
functional in altering the bioenergetic and biosynthetic state of cancer cells. Also, the reduction of
OXPHOS capacity is not present in all tumors: in breast cancer, upregulation of OXPHOS has been
demonstrated [12], while the transcriptome analysis of pancreatic tumor-initiating cells revealed a
prominent expression of genes involved in mitochondrial function and an increased consumption
of oxygen. Recent studies have indeed indicated that, while glycolysis is drastically upregulated in
almost all cancer cells, mitochondrial respiration continues to operate normally, at rates proportional
to the oxygen supply [17]. However, OXPHOS impairment has been found in diverse cancer types and
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some mechanisms have been proposed: mutations of the Krebs cycle enzymes in pituitary and renal
tumors [18,19], the absence of one of the principal enzymes controlling respiratory complex I in renal
oncocytoma [20], and the activation of oncogenes (K-RAS), and transcription factors (HIF1-alpha) [21]
in mouse transformed fibroblasts.
Since ROS content in cancer cells is generally increased, in order to maintain the steady-state
concentrations of ROS, mitochondria must rely on their own antioxidant system for the scavenging
and neutralization of the radicals generated by OXPHOS [22,23]. Dismutation of mitochondrial
matrix superoxide (O2´) into H2O2 is catalyzed by Mn superoxide dismutase (MnSOD, SOD2), while
dismutation of intermembrane space O2´, which is primarily generated by respiratory complex III [24],
is catalyzed by intermembrane and cytosolic Cu/ZnSOD (also known as SOD1). Another enzyme
located in the mitochondria, methylene-tetrahydrofolate dehydrogenase 2 (MTHFD2), which uses
NAD+ as a coenzyme [25], is overexpressed in rapidly proliferating malignant tumors. It has been
postulated that this enzyme constitutes the “main switch” that enables mitochondria to produce
additional one-carbon units for purine synthesis in rapidly growing tumor cells, and generates the
NADH necessary for the protection from ROS and macromolecular syntheses [26,27]. Interestingly,
this mitochondrial enzyme is overexpressed in rapidly growing tumor tissues and not in replicating
normal tissues, and the knockdown of MTHFD2 has an antiproliferative effect, suggesting that the
inhibitors of this enzyme may be employed in cancer treatment [28].
2.2. MtDNA Mutations in Cancer Cells
Human mitochondria contain copies of a circular DNA encoding 13 polypeptide components
of the OXPHOS system, 12S and 16S ribosomal RNA and 22 transfer RNAs [29]. The remaining
mitochondrial proteins are encoded by the nuclear DNA. Each cell contains a number of mitochondria,
and each mitochondrion contains several copies of mtDNA. Thus, the mtDNA mutations, generated
by ROS attack, can be passed to daughter cells together with normal mtDNA, in a heteroplasmic state.
However, it is possible that a subpopulation of cancer cells present all mtDNA copies mutated [30].
In normal mammalian cells, mtDNA has a higher mutation frequency, compared to nDNA [31,32], due
to its location in the vicinity of ROS-producing OXPHOS and the lack of protective histones [33,34].
Several mtDNA mutations were reported in a wide variety of tumors. Mutations in mtDNA genes
have been detected in colorectal cancer [35] and in gastric, bladder, lung, renal, prostate, and
ovarian cancer [36–38]. However, in the majority of tumors, the high frequency and complexity
of mtDNA mutations have made it difficult to understand their role in carcinogenesis [39]. Moreover,
the functional interpretation of many of the mutations remains ambiguous, and few studies have
demonstrated a direct relationship between mtDNA mutations and carcinogenesis. In favor of the
involvement of mtDNA mutations in carcinogenesis, Petros et al. [40] demonstrated that mtDNA
mutations play an important role in the pathogenesis of prostate cancer. These authors generated
a pathogenic mtDNA T8993G mutation in the gene-encoding ATP synthase (complex V) subunit
ATP6, in PC3 prostate cells, through cybrid transfer, and tested for tumor growth in nude mice. The
mutant (T8993G) cybrids generated tumors that were seven times larger than the wild-type (T8993T)
cybrids. Moreover, they found significantly more ROS in the mutant tumors [40]. Other authors
demonstrated a direct involvement of mtDNA mutations in the induction of metastatic potential of
Lewis lung carcinoma cells, fibrosarcoma cells and colon cancer cells, by using assays of metastasis in
mice. The mtDNA conferring high metastatic potential contained G13997A and 13885insC mutations
in the gene-encoding NADH-ubiquinone oxidoreductase (complex I) subunit ND6. These mutations
produced a deficiency in respiratory complex I activity and were associated with overproduction of
ROS. Interestingly, pretreatment of the highly metastatic tumor cells with ROS scavengers suppressed
their metastatic potential in mice [41]. Overall, it is generally accepted that mtDNA mutations are
responsible for the induction of ROS production at the expense of a loss of efficiency of the electron
transfer chain. ROS, in turn, can induce mtDNA mutations and activate several signaling pathways
critical for tumor growth and maintenance [42].
Antioxidants 2016, 5, 7 4 of 25
Besides mtDNA mutations, several studies demonstrated a variation in the number of mtDNA
copies in various types of cancer [38]. However, both increases and decreases in the number of mtDNA
copies have been reported to be associated with an increased risk of tumorigenesis. Thus, the role of
the variations in the number of mtDNA copies in cancer is still a subject of debate.
3. Lipid Composition and Lipoperoxidation in Mitochondria of Cancer Cells
In mitochondria, more than in other subcellular organelles, the lipid component of membranes
plays a fundamental role in regulating a wide range of mitochondrial and cellular functions, including
respiration, programmed cell death, and autophagy/mitophagy. Moreover, mitochondrial lipids
coordinate shifts of several proteins among subcellular compartments [43]. The importance of lipids
in controlling mitochondrial functions is further confirmed by several observations: (1) lipid types,
in particular phospholipid classes, differ in the two mitochondrial membranes (outer mitochondrial
membrane, OMM, and inner mitochondrial membrane, IMM), indicating a specific correlation between
lipid composition and the functions that they carry out; (2) mitochondria have the capacity to synthesize
some phospholipid classes; (3) mitochondria from different cell types and different species share the
above characteristics.
3.1. Lipid Composition and Mitochondrial Functions in Normal and Cancer Cells
In both the outer (OMM) and the inner (IMM) mitochondrial membrane, the main
phospholipids are phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol
(PI), phosphatidylserine (PS), and phosphatidic acid (PA). Besides these major phospholipids classes,
which are also present in other cellular membranes, mitochondrial membranes exclusively contain
cardiolipin (CL) and phosphatidylglycerol (PG). Unlike in other cell membranes, the percentages of
sphingolipids and cholesterol in mitochondrial membranes are rather low [44,45]. The differences in
percentage content of phospholipids classes in OMM and in IMM are reported in Table 1 [46].
Table 1. Percentage content of different phospholipid classes in mammalian mitochondria [46].
Phospholipids Percentage Content
OMM IMM
Phosphatidylcholine 54 40
Phosphatidylethanolamine 29 34
Phosphatidylinositol 13 5
Phosphatidyserine 2 3
Cardiolipin <1 18
Others <1 0
OMM, outer mitochondrial membrane; IMM, inner mitochondrial membrane.
OMM and IMM also differ from other cell membranes with regard to the protein/lipid ratio.
In general, in mitochondria this ratio is lower than in other subcellular organelles, and IMM shows
a higher protein level and a lower lipid content than OMM [45,46]. In spite of the low lipid content
in IMM, it is known that mainly CL and PE are crucial for the activity of several mitochondrial
proteins, including adenine nucleotide translocator and ATP synthase, and functions, such as oxidative
phosphorylation, mitophagy, and apoptosis [47,48].
As already mentioned, mitochondria have the capacity to synthesize some phospholipid classes,
in particular CL, PE, PG, and PA. The synthesis of CL takes place in the inner (matrix) side of IMM
and is regulated by several factors. PE is formed by decarboxylation of PS in the IMM, and this
process produces almost all the required PE. Moreover, the PE produced can be exported out of the
mitochondria. The import/export of phospholipids into and out of the mitochondria can occur in
different ways: (1) spontaneous transport; (2) via contact sites in the membranes; (3) via the activity
of phospholipids scramblases (flippases) responsible for the bidirectional phospholipid transport;
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(4) via vesicular transport [49–52]. The different phospholipid classes are not evenly allocated in
mitochondrial membranes, but they show an asymmetric distribution. For example, in IMM the
percent localization of PC and PE is similar in the side facing the intermembrane space and the matrix
side, whereas CL and PI are mainly (about 80%) located in the side facing the matrix [46,53].
Both biochemical and functional properties of different phospholipid classes are strongly
influenced by their fatty acid component. It is well known that in most mitochondria, linoleic acid (LA)
is the main PUFA in CL (about 80%), and that a decreased percentage content of LA negatively affects
COX activity [54–56]. Differently, in brain mitochondria, the acyl moiety of CL mainly consists of long
chain PUFAs, including docosahexaenoic acid (DHA, C22:6) and arachidonic acid (AA, C20:4) [57].
Saturated palmitic acid (C16:0) is the most abundant fatty acid in testicular CL, and probably protects
spermatozoa from LPO [58,59]. The fatty acid composition of mitochondrial membrane phospholipids
is known to be influenced by two main factors: the intra-mitochondrial fatty acid synthesis and the
pattern of fatty acids present in the diet [60]. Eukaryotic cells possess a highly conserved mitochondrial
pathway for fatty acid synthesis, which is completely independent of the one that is working in
the cytoplasm. The mitochondrial machinery synthesizing fatty acids consists of mono-functional
polypeptides not yet well characterized in human beings [61,62]. Nevertheless, it has been reported
that these enzymes show a wide substrate specificity, and act on short-chain substrates (C2 up to
C16) [62].
With regard to the importance of dietary fatty acids, several studies have evidenced that changes
in the fatty acid content of food significantly modify mitochondrial phospholipids, and in particular
CL properties, the effects being also related to the different types of cells. Conversely, a recent
lipidomic-based analysis concluded that fatty acid content in CL does not directly reflect the dietary
fatty acid content, but is rather a result of a specific selections [63]. The analysis of the changes
occurring in mitochondrial membrane phospholipids in aging evidenced an increased content of
DHA-containing phospholipids, mainly in PC and in PE [64]. Overall, the most important role in
modulating fatty acid composition and functions in mitochondria seems to be played by dietary PUFAs,
and in particular by n-3 ones, even though the effects are once again related to phospholipid classes
and cell types. In general, PC seems to be more affected by the variation of dietary monounsaturated
fatty acids (MUFAs), whereas PE is more responsive than PC to the dietary content of n-6 and n-3
PUFAs [65].
Concerning the importance of the differences in fatty acid composition of mitochondria from
various tissues, it has been reported that the presence of four linoleic acyl chains in CL is essential for
the optimal function of heart mitochondria; moreover, it has been recently observed that n-3 PUFA
supplementation, even though increasing the production of ROS, did not induce oxidative damage
and favored mitochondrial membrane reorganization in human skeletal muscle [66]. In agreement
with these studies, a high intake of DHA- and EPA-enriched fish oil prevented the age-associated
increase of PC [67].
In the light of the importance of phospholipid classes and of fatty acid content in regulating
mitochondrial and overall cellular functions, the changes in lipid composition in carcinogenesis
have been investigated, mainly in animal models and in cultured cancer cells. The reported
modifications in the mitochondrial lipid profile concerned both neutral and polar lipids. In
mitochondria from hepatocarcinoma, the following changes have been observed: (1) an increase
in cholesterol/phospholipid ratio; (2) a decreased content of polyenoic acyl chains in phospholipids;
(3) a diminished ability to undergo volumetric and conformational changes; (4) an increased lability of
the phosphorylating machinery.
The modifications of the fatty acid composition of phospholipid classes observed by
Canuto et al. [68] in mitochondrial membranes during diethylnitrosamine carcinogenesis in rat liver
are reported in Table 2.
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Table 2. Monounsaturated and polyunsaturated fatty acid content in phospholipid classed of
mitochondria isolated from rat liver hepatoma.
Tissues/Cells
Phophatidyl´
Choline
Phophatidyl´
Ethanolamine
Phosphatldylserine+
Phosphatidylinositol Cardiolipn
MUFA PUFA MUFA PUFA MUFA PUFA MUFA PUFA
Normal liver 11.41 37.11 7.08 43.11 6.84 30.18 18.04 55.46
Nodules 23.62 27.24 19.06 34.85 14.44 24.89 25.37 36.27
Hepatoma 29.68 25.68 22.57 37.78 22.12 25.64 28.54 23.72
AH-130
Hepatoma 25.33 26.28 18.54 47.21 17.83 28.23 22.17 28.75
MUFA, sum of monounsaturated fatty acids; PUFA, sum of polyunsaturated fatty acids [68].
The reported results evidenced that changes in the MUFA/PUFA ratio are an early event in
hepatocarcinogenesis, already detectable in preneoplastic lesions (nodules), and that a MUFA increase
and PUFA decrease are present also in highly deviated AH-130 ascites hepatoma. Conversely, no
significant change in the fatty acid profile has been observed by other authors in the mitochondria
isolated from rat liver nodules induced by a 2-acetylaminofluorene-containing diet [69]. It is possible
that this discrepancy is due to the different times at which the nodules were analyzed; in fact, in
the first study, fatty acid analysis was carried out between 7 and 10 months after exposure to the
carcinogenic agent, and after 25 weeks in the second study.
The increased MUFA and decreased PUFA content, reported by Canuto et al. [68], have been
observed also in some types of Morris hepatomas showing different growth rates and malignancy
degrees [70]. In particular, a decreased content of AA has been observed in total phospholipids
extracted from normal rat hepatocytes and rat hepatoma cell lines 7777 and JM2 [71].
It was speculated that the previously reported modifications in phospholipid classes and fatty
acid content in mitochondria from cancer cells might be responsible for several characteristics of cancer
cells, including their different susceptibility to mitochondrial-driven apoptosis. In this regard, it has
been evidenced that the incorporation of PUFAs in cardiolipin is able to induce apoptosis via transition
pore opening, mitochondrial potential decrease and caspase-9 and caspase-3 activation [72].
3.2. Lipid Catabolism and Reactive Oxygen Species (ROS) Production in Cancer Cells
Lipid catabolism in cancer cells is generally increased, as demonstrated in human
hepatocarcinoma HepG2 cells, where lipid catabolism may replenish the mitochondrial acetyl-CoA
pool required for OXPHOS [73]. Moreover, high carnitine-acyl-transferase 1 (CPT1) mRNA contents
have also been found in ovary, colon, esophageal, prostate and colorectal carcinomas, as well as in
Zadjela hepatoma and K-RAS transformed fibroblasts [74–76]. These results show that β-oxidation of
mitochondrial free fatty acids is certainly functional in cancer cells, driving the OXPHOS-dependent
ATP supply for cell proliferation. Nevertheless, some results from other groups did not seem to be
in agreement with these observations. For example, during tumor cell proliferation, growth-factor
signaling suppressed β-oxidation of fatty acids, minimizing futile cycling and maximizing lipid
synthesis [77]. Thus, it has been suggested that fatty acid oxidation in cancer cells may be
context-dependent or cancer cell-type specific [78]. The changes in fatty acid β-oxidation, together
with other variations affecting the integration between metabolic pathways, which in part can involve
mitochondria, such as the levels of amino acid intermediates and the activity of the pentose phosphate
pathway, likely entail redox state perturbations. Moreover, hypoxia, caused by inadequate oxygen
supply from the local vasculature, results in increased generation of ROS and cell death [79]. As a
consequence, the extent of the alterations induced by ROS and by their peroxidative products on whole
cells and mitochondria is increased in cancer cells. One of the targets of ROS is mitochondrial mtDNA,
which encodes several proteins important for the function of the mitochondrial electron transport
chain and for ATP synthesis by OXPHOS [29]. As mentioned before, mtDNA is highly susceptible
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to attack by ROS, owing to its close proximity to the electron transport chain, the major site of free
radical production, and the lack of protective histones. Therefore, mtDNA oxidative damage could
lead to the loss of mitochondrial electron transport, membrane potential and ATP generation [80].
Moreover, the peroxidation of PUFAs in mitochondrial membranes induced by ROS leads to the
production of reactive aldehydes which, in turn, can contribute to the inhibition of enzyme activities,
as demonstrated by Raza et al. [81]. It has been postulated that high HNE concentrations can also alter
mitochondrial functions through the formation of adducts with mtDNA, similar to those observed in
nuclear DNA [82]. Oxidative damage, directly or indirectly induced by ROS, is probably the major
source of mitochondrial genomic instability leading to respiratory alterations, and is responsible,
among other consequences, for the mitochondrial dysfunctions observed in cancers, particularly in the
most aggressive and rapidly growing ones (Figure 1) [80–83].Antioxidants 2016, 5, 7 7 of 24 
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Indeed, it has been demonstrated that the IMM is rich in CL, which contributes greatly to its 
unsaturated nature. The acyl chain composition of CL in humans and rodents includes primarily LA, 
the relative abundance of this fatty acid in mouse CL ranging from 60% in skeletal muscle to more 
than 80% in the heart and the liver [86]. Several experimental results demonstrated that the oxidation 
of mitochondrial CL also leads to the formation of a significant amount of HNE, MDA and other 
oxidation products [87,88]. It has been shown that the reaction of HNE with hepatic mitochondrial 
membranes results in altered lipid-lipid and protein-lipid interactions. This occurs through a variety 
of mechanisms, including cross-linking of lipid tails, which limits phospholipid mobility in the lipid 
bilayer [89]. Overall, the studies on the effects of LPO on membrane physiology demonstrate a 
marked reduction in membrane fluidity [90,91] and an increase in membrane permeability [92,93]. 
Alterations of mitochondrial membranes, mainly due to the increased mitochondrial LPO, have 
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Figure 1. Effects of mitochondrial ROS in cancer cells.
In cancer cell mitochondria the level of ROS is generally increased, due to multiple inputs that
regula e the generation of ROS (e.g., ypoxia and onc genes). The mitochondrial ROS generate
mtDNA mutations, leading to mitochondrial dysfunctions and apoptosis, protein oxidation and lipid
peroxidation. Lipid peroxidation leads to the production of aldehydes, in particular HNE which, in
turn, can bind and inactivate mitochondrial proteins. ROS released from mitochondria can induce
lipid peroxidation of cellular membranes, nuclear DNA damage, which contribute to the apoptosis
induction, and transcription factor activation.
3.3. Lipid Peroxidation and Its Products
Some ROS can oxidize virtually any biological macromolecule, but PUFAs represent the main
target f intracell lar oxidizin agents. Many of the produ s of lipid oxidati n are chemi lly reactive
and capabl of ndu ing alterations n cell signaling and survival, through their ability to modify
various cellular targets [84]. Among them, the reactive HNE is the most studied because of its ighest
biological activity. HNE is derived from the decomposition of n-6 PUFAs. Phospholipids containing
LA (18:2, n-6) and AA (20:4, n-6) in extra mitochondrial membranes are considered the major source
of HNE production [85]. However, HNE can be produced in mitochondria too. Indeed, it has been
demonstrated that the IMM is rich in CL, which contributes greatly to its unsaturated nature. The acyl
chain composition of CL in humans and rodents includes primarily LA, the relative abundance of this
fatty acid in mouse CL ranging from 60% in skeletal muscle to more than 80% in the heart and the
liver [86]. Sev ral experimental results demonstrated that the oxidation of mitochondrial CL also leads
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to the formation of a significant amount of HNE, MDA and other oxidation products [87,88]. It has been
shown that the reaction of HNE with hepatic mitochondrial membranes results in altered lipid-lipid
and protein-lipid interactions. This occurs through a variety of mechanisms, including cross-linking
of lipid tails, which limits phospholipid mobility in the lipid bilayer [89]. Overall, the studies on the
effects of LPO on membrane physiology demonstrate a marked reduction in membrane fluidity [90,91]
and an increase in membrane permeability [92,93]. Alterations of mitochondrial membranes, mainly
due to the increased mitochondrial LPO, have been detected after pro-oxidant cisplatin treatment in
kidney and Dalton’s lymphoma cells, which showed more roundish mitochondria with thickened
membranes, numerical reductions and irregularities in the shape of cristae and intramitochondrial
vacuoles [94]. However, no data have been provided thus far on the perturbations of mitochondrial
membrane functions possibly associated with the above-described modifications.
3.4. 4-Hydroxynonenal (HNE)-Protein Adducts in Cancer Cell Mitochondria
HNE can easily react with several cellular proteins and affect their function [95]. In particular, it
has been demonstrated that mitochondrial proteins can represent a suitable target for the production
of HNE adducts [88]. By using a proteomic approach, involving two-dimensional electrophoresis,
followed by mass spectrometry and investigation of protein databases, Zhao et al. [96] identified several
HNE-modified mitochondrial proteins in cardiac mitochondria from doxorubicin-treated mice. The
majority of the identified proteins were related to mitochondrial energy metabolism, such as certain
enzymes of the citric acid cycle and the electron transport chain, whose modifications negatively
affected their enzymatic activities and the respiratory function of cardiac mitochondria. Treatment
with Mn (III) meso tetrakis (N-n-butoxyethylpyridinium-2-yl) porphyrin, a SOD mimic, averted the
doxorubicin-induced mitochondrial dysfunctions, as well as the formation of HNE-protein adducts.
Functional inactivation is a common consequence of the covalent modification of enzymes by HNE.
Other results by Doorn et al. showed that HNE inhibited mitochondrial aldehyde dehydrogenase 2
(ALDH2), as a consequence of the formation of a HNE-cysteine adduct at the ALDH2 active site [97].
Studies from Asian countries evidenced a significant association between ALDH2 enzyme deficiency
and esophageal cancer risk [98]. It might be speculated that HNE might participate in carcinogenesis,
also due to its inhibitory effect on ALDH2 activity. The interaction of HNE with cellular proteins has
been evoked in support of both its carcinogenic and anti-carcinogenic roles, depending on the particular
HNE-modified protein and the biological consequences of its modification [9,84,99]. However, the
ability of HNE to alter mitochondrial function is not always a consequence of HNE-mitochondrial
protein adduct formation, but it might also depend on the reduction of the cellular content of
detoxifying molecules, such as GSH, resulting in the maintenance of high intracellular levels of
ROS [100]. This hypothesis has been confirmed by Raza et al. [81], who found that HNE treatment of
PC12 pheochromocytoma cells caused a reduction in the GSH pool and a marked inhibition in the
activities of mitochondrial enzymes cytochrome c oxidase and aconitase. Until now, comprehensive
studies of HNE-protein adducts and of HNE effects on mitochondrial functions in diverse cancer
types have not been presented. The presence of nuclear and mitochondrial HNE-protein adducts
in both normal proximal renal tubule and in three types of renal carcinoma has been reported, but
no characterization of the proteins involved and of the functional consequences of adduct formation
has been provided [101]. Mitochondrial HNE-protein adducts have been found in a multistage skin
carcinogenesis model during papilloma formation, suggesting that the presence of these adducts might
be involved in cutaneous carcinogenesis [102].
Specific HNE protein adducts have been identified by Li et al., who showed that HNE inhibited,
by thiol-specific modification, the deacetylase activity of Sirtuin-3 (SIRT3), a major mitochondrial
NAD+-dependent deacetylase, leading to increased angiogenesis and invasion of breast cancer
cells [103]. Zhang et al. demonstrated that the thioredoxin reductase (TrxR), the only known enzyme
catalyzing Trx2 reduction in mitochondria, was sensitive to inactivation by HNE, and that this effect
might account for the induction of apoptosis by HNE in HeLa cancer cells. [104]. Other investigators
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showed that HNE was able to trigger apoptosis of human colorectal carcinoma (RKO) cells and RAW
264.7 cells, through a mitochondrion-dependent pathway [105,106].
An overview of the effects of HNE on mitochondrial proteins and functions in different types of
cancer cells is provided in Table 3.
Table 3. HNE effects on mitochondrial proteins in cancer models.
Cancer Model Protein Targets MitochondrialFunction HNE Effect Reference
PC12 pheochromocytoma
cell line
cytochrome c
oxidase aconitase
respiratory
enzymes inhibition [81]
Kidney cancers HNE-mitochondrialprotein adducts [101]
Skin carcinogenesis HNE-mitochondrialprotein adducts - - [102]
Breast cancer cells
sirtuin 3 (SIRT3)
HNE-SIRT3
adducts
NAD+-dependent
deacetylase inhibition [103]
HeLa cervical
adenocarcinoma cell line
thioredoxin
reductase (TrxR) Trx reduction inhibition [104]
RKO colorectal
carcinoma cell line -
cytochrome c
release induction [105]
RAW 264.7 mouse
monocytic/macrophagic
leukemic cell line
- cytochrome crelease induction [106]
Moreover, although increased oxidative stress has been demonstrated in the majority of cancer
types [99], the concentration of LPO products, such as HNE, was not increased in every one of them,
possibly varying in relation with the composition of cell membranes and metabolizing enzymes.
Indeed, both decreased and increased HNE concentrations, compared with normal tissues, have been
reported in cancer tissues, depending on the tumor type or the presence of inflammation [69,72,84].
In conclusion, even though increased ROS production and ROS-induced mtDNA mutations have been
found to be related to carcinogenesis, the presence of covalent modifications of mtDNA with HNE and
other lipid electrophiles and the direct involvement of HNE adducts with mitochondrial proteins in
the pathogenesis of cancer remain aspects that still require further investigation.
4. Oxidative Stress and Mitochondrial Dysfunction in Neurodegenerative Disease
Oxidative stress is implicated in the pathogenesis of most neurodegenerative diseases, including
Alzheimer’s disease (AD), tauopathies and alpha-synucleinopathies, i.e., Parkinson’s and related
diseases (PD) and Huntington’s disease (HD). Oxidative damage occurs in early stages of AD [107–110].
Oxidative alterations of proteins by ROS have been implicated in the progression of neurodegenerative
disorders. In fact, high levels of markers of LPO have been found in brain tissues and body
fluids in the above-mentioned diseases [111–114]. Novel 2,4-diphenylhydrazine (DPNH)-reactive
carbonyl groups in proteins, susceptible to spectrometric or antibody-mediated detection, might
be either produced by the direct metal-catalyzed oxidation of aminoacyl side chains or introduced
by stable adduct formation via the reaction of lysyl residues with reducing sugars and third-party
reactive carbonyl species (RCS). As some of these, like glyoxal and methylglyoxal, might derive from
free-radical attack to derivatives of both carbohydrate and lipid metabolism [115], their adducts
with lysyl residues of proteins are referred to as mixed advanced glycoxidation end products
(AGEs)/advanced lipoxidation end products (ALEs) [116]. Typical LPO products, formed upon
the free-radical attack to PUFAs, include acrolein, MDA and HNE. They exert toxic effects upon cells,
Antioxidants 2016, 5, 7 10 of 25
by altering several of their functions, mostly by forming covalent adducts with cell proteins [117].
The immunodetection of protein-bound N-(malondialdehyde)-lysine (MDAL) and HNE adducts
with cysteinyl, histidyl and lysyl residues in proteins has been largely exploited as a measure of
lipid peroxidation in neurodegenerative diseases [116,118,119]. Inventories of modified cellular
proteins were compiled by several authors, who investigated the consequences of increased oxidation,
glycoxidation or lipoxidation in the course of oxidative stress, by the means of redox proteomic
approaches, combining bidimensional gel electrophoresis, Western blotting with oxidative markers
and mass spectrometry [107,109,116,119–121]. Vulnerable proteins could be assigned to a few distinct
functional groups, with crucial roles in membrane transport, energy metabolism, mitochondrial
function, antioxidant defenses, cellular stress responses, cell signaling, signal transduction, cytoskeletal
organization, protein synthesis and neurotransmission (reviewed in [108,120,122,123]). It appears
from these studies that in neurodegenerative diseases the generation of adducts of LPO products with
several cell proteins is associated with losses of specific functions, which, in turn, might cause the
progressive endangerment of vital processes, ultimately leading to neuronal death [93]. Moreover, in
AD, by reacting directly also with amyloid beta peptide (Aβ), HNE exacerbated the aggregation and
toxicity of Aβ oligomers, which, in turn, enhanced oxidative stress and LPO, thus fueling a vicious
circle of toxic Aβ oligomer formation [108,120,124].
The involvement of mitochondria in the pathogenesis of neurodegenerative disorders has been
suggested in consideration both of the mtDNA mutations that can be caused by ROS [125,126], and of
the frequent participation of several mitochondrial proteins in the formation of covalent adducts of
LPO products. We focus here on the structural and functional consequences of these modifications.
5. Role of the Adducts of Aldehydes Derived from Lipid Peroxidation with Mitochondrial
Proteins in Neurodegeneration
The detection of protein adducts with LPO products by redox proteomic approaches was often
only circumstantially associated with a disease. Functional studies of target proteins, especially with
regard to adduct formation in the disease context, have not been always provided. In an attempt to
investigate further the possible impact of the oxidative modifications of mitochondrial proteins on the
neuronal dysfunctions observed in neurodegenerative diseases, we provide here, in addition to an
account of the adducts of LPO products with mitochondrial proteins so far identified and the related
functional studies, whenever present in the literature (Table 4), also a description of the mutations of
the respective genes and the associated phenotypes, retrieved in the Online Mendelian Inheritance in
Man (OMIM) database [127].
Table 4. Adducts of aldehydes derived from lipid peroxidation with mitochondrial proteins in
neurodegenerative diseases, in relation with clinical progression.
Protein AD Stage Function Reference
HNE-modified proteins
Aconitate hydratase, mitochondrial
(Aconitase 2, ACO2) LAD
energy metabolism,
mitochondrial function [121]
ATP synthase (complex V) alpha
subunit 1 (ATP5A1) PAD, MCI, EAD, LAD
energy metabolism, ATP
production [109,110,121,128]
Translation elongation factor Tu
(EF-Tu, TUFM) MCI protein synthesis [109]
Malate dehydrogenase 2,
mitochondrial (MDH2) EAD
energy metabolism,
gluconeogenesis [110]
Mn Superoxide dysmutase,
mitochondrial (SOD2) EAD, LAD antioxidant defense [110,121]
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Table 4. Cont.
Protein AD Stage Function Reference
MDA-modified proteins
Ubiquinol-cytochrome c reductase
(complex III) core protein 1 (UQCRC1) LAD
electron transport, ATP
production [116]
ATP synthase (complex V) beta
subunit (ATP5B) LAD
energy metabolism, ATP
production [116]
60-kDa Heat shock protein
(HSPD1, HSP60) LAD stress response [116]
Glutamate dehydrogenase 1,
mitochondrial (GDH1) LAD energy metabolism [116]
Proteins with increased content of DPNH-reactive groups
Aconitate hydratase, mitochondrial
(Aconitase 2, ACO2) HD
energy metabolism,
mitochondrial function [129]
Citrate synthase, mitochondrial (CS) HD energy metabolism [130]
Creatine kinase B, ubiquitous
mitochondrial (CKMT1A) HD ATP production [130]
Ubiquinol-cytochrome c reductase
(complex III) core protein 2 (UQCRC2) HD
electron transport, ATP
production [130]
ATP synthase (complex V) alpha
subunit 1 (ATP5A1) HD
energy metabolism, ATP
production [130]
DJ-1 (Parkinson protein 7, PARK7) PD, AD antioxidant defense [131]
NADH-ubiquinone oxidoreductase
(complex I) PD
electron transport, ATP
production [132]
PAD, preclinical Alzheimer’s disease (Braak I/II stage); MCI, amnestic mild cognitive impairment (follows in
time PAD and precedes EAD, during AD progression); EAD, early-stage Alzheimer’s disease; LAD, late-stage
Alzheimer’s disease; HD, Huntington’s disease; PD, Parkinson’s disease.
The concept at the base of this approach is that genetic mutations and oxidative modifications of
proteins may represent different ways of altering the integrity of cell proteins, to a point where disease
manifestations occur. The genetic and acquired modifications of Cu, Zn-superoxide dismutase (SOD1),
a key antioxidant enzyme whose mutations have been linked to the autosomal dominant familial form
of amyotrophic lateral sclerosis (ALS), may represent a reference model for this hypothesis. The SOD1
pI 6.0 isoform was found to be oxidatively modified by carbonylation in human brain post-mortem
samples from AD and PD patients. Moreover, Cys146, a residue of SOD1 that is mutated in familial
ALS, was oxidized to cysteic acid in the same brain samples. In AD brains, SOD1 formed proteinaceous
aggregates associated with amyloid senile plaques and neurofibrillary tangles. These data implicate
oxidative damage to SOD1 in the pathogenesis of sporadic AD and PD [133].
5.1. HNE-Modified Mitochondrial Proteins
5.1.1. Mitochondrial Aconitate Hydratase (Aconitase 2, ACO2)
Mitochondrial aconitate hydratase (aconitase 2, ACO2) catalyzes step 2 in the Krebs cycle, i.e., the
reversible isomerization of citrate to isocitrate, via the dehydration of citrate to cis-aconitate, followed
by the hydration of cis-aconitate to isocitrate. There is an extensive documentation on ACO2 as a target
of oxidative stress, due to the high sensitivity of its Fe-S cluster (reviewed in [134]). Chen et al. showed
that yeast mitochondrial aconitase is essential for mitochondrial DNA maintenance, independent of
its catalytic activity [135]. HNE adducts with ACO2 were detected in the hippocampus of patients
with late-stage AD (LAD), in 185% excess over control brain samples; investigation of the functional
consequences of the modification revealed that the enzymatic activity of ACO2 was reduced by 50%,
supporting the view that oxidative modification determined functional impairment [121].
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In this context it is of interest that the mutations of the ACO2 gene are associated with infantile
cerebellar-retinal degeneration (ICRD, MIM 614559), a severe autosomal recessive, neurodegenerative
disorder, characterized by onset between ages two and six months of truncal hypotonia, athetosis,
seizures and ophthalmologic abnormalities, such as optic atrophy and retinal degeneration. Affected
individuals show profound psychomotor retardation, with only some achieving rolling, sitting, or
recognition of family. Brain MRI shows progressive cerebral and cerebellar degeneration. Allelic
mutations of the same gene are also associated with optic atrophy 8 (OPA 8, MIM 616289), a progressive
visual loss in association with optic atrophy, reflecting a deficiency in the number of nerve fibers which
arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts.
5.1.2. Mitochondrial Adenosine Triphosphate (ATP) Synthase (Respiratory Complex V), Alpha
Subunit 1 (ATP5A1)
ATP synthase (Respiratory Complex V, EC 3.6.3.14) is a multimeric complex located in the IMM,
consisting of two fractions (F1 and FO) and at least 16 polypeptides, two of which (MT-ATP6, MT-ATP8)
are encoded by mitochondrial genes and the remainder by nuclear genes. The FO (oligomycin-binding)
fraction is a proton pore embedded within the inner mitochondrial membrane, while the F1 fraction
projects into the mitochondrial matrix. ATP synthase catalyzes the synthesis of ATP from ADP and
inorganic phosphate by coupling it with a flow of protons from the mitochondrial intermembrane
space to the matrix.
Mitochondrial dysfunction, with reduced glucose utilization and decreased ATP synthase activity
and energy production, is an early occurrence in the pathogenesis of AD [136,137]. Significant increases
in the levels of HNE-modified ATP synthase alpha subunit, accompanied by a 30% reduction in ATP
synthase activity (at variance with respiratory complex I, whose activity was unaltered), were observed
in post-mortem homogenates of entorhinal cortex in early, clinically silent cases of AD in Braak stages
I/II, in comparison with control samples [128]. ATP synthase alpha chain was also one of several
proteins with markedly increased levels of HNE adducts in the hippocampus (660% over control
levels) and in the inferior parietal lobule (IPL) (450% over control levels) of patients with amnestic mild
cognitive impairment (MCI), a condition of increased risk for AD. ATP synthase alpha subunit was the
only HNE-modified protein identified in both anatomical locations. ATP synthase activity was reduced
by 35% in the hippocampus and by 30% in the IPL of MCI brains, compared with controls [109]. The
relative increase of HNE-modified ATP synthase alpha chain in the IPL of patients with early AD (EAD)
was marginal, with a 20% activity reduction [110], while in late-stage AD (LAD) the relative increase
of HNE-modified ATP synthase alpha chain in the IPL was 250% over control samples, while ATP
synthase activity was decreased by 48% and the protein level was also decreased in comparison with
controls, suggesting that the oxidative impairment of ATP synthase activity might be accompanied by
downregulation of the expression or destabilization of the protein product [121].
Taken together, these data favor the view that the modification of cell proteins with LPO products
is an early event in the progression of AD and is associated with impairments of enzymatic activity and
cell functions. Furthermore, it was suggested that oxidation of ATP synthase alpha subunit, besides
compromising ATP synthesis, might also enhance ROS production, resulting in a vicious cycle of
mitochondrial dysfunction and neuronal damage [128,138].
Mutations of the ATP5A1 gene, encoding the alpha subunit of the ATP synthase F1 fraction,
are associated with two phenotypes of human disease: mitochondrial complex V (ATP synthase)
deficiency, nuclear type 4 (MC5DN4, MIM 615228), which is an autosomal recessive, fatal form of
infantile encephalopathy, and combined oxidative phosphorylation deficiency 22 (COXPD22, MIM
616045), also an autosomal recessive disorder, resulting in early death.
Several other types of complex V ATP synthase deficiency have been described, in association
with the mutations of nuclear and mitochondrial genes encoding other complex V subunits. Among
them, most interesting is ATP synthase deficiency, mitochondrial type 1 (MC5DM1), associated with
mutations of the MTATP6 gene and with several disease phenotypes:
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(a) Leigh syndrome (LS, Necrotizing encephalopathy, infantile subacute, SNE, MIM 256000). This is
an early-onset, progressive neurodegenerative disorder, with bilateral foci of demyelination,
necrosis, gliosis, spongiosis or capillary proliferation in one or more areas of the central
nervous system (brainstem, thalamus, basal ganglia, cerebellum and spinal cord). Patients
exhibit psychomotor retardation, epilepsy, cerebellar and motor disturbances, extraocular
muscle incoordination, neurogenic breathing disorders, neural deafness, retinitis pigmentosa,
polyneuropathy, lactic acidosis, and cardiomyopathy. LS is genetically heterogeneous, being
associated with the defects of several mitochondrial- and nuclear-encoded subunits and assembly
factors of respiratory complexes IV, I (most often), but also V, III, mitochondrial tRNAs and other
nuclear-encoded mitochondrial proteins, such as pyruvate dehydrogenase E-1α subunit.
(b) LHON (Leber Hereditary Optic Neuropathy, MIM 535000). LHON presents in midlife as acute or
subacute central vision loss, with peripapillary microangiopathy and telangiectasia, to central
scotoma and blindness, inherited with a maternal pattern of transmission. Disturbances of cardiac
conduction and dystonia may coexist. The disease has been associated with many allelic missense
mutations in the mtDNA that can act autonomously or in association with each other to cause
the disease. LHON is also genetically heterogeneous, possibly reflecting mutations of most
mitochondrially encoded subunits of respiratory complexes I, III, IV and V.
(c) NARP (Neurogenic muscle weakness, Ataxia, and Retinitis Pigmentosa, MIM 551500). This
syndrome entails a combination of developmental and psychomotor retardation, retinitis
pigmentosa, dementia, seizures, clonic spasms, ataxia, proximal neurogenic muscle weakness,
sensory neuropathy, hearing loss and optic atrophy, with a maternal pattern of transmission, with
no histochemical evidence of myopathy. Mattiazzi et al. [139] showed that the T8993G mutation
of the ATP6 gene inhibited oxidative phosphorylation and enhanced free radical production.
Antioxidants restored respiration and partially rescued ATP synthesis in cells harboring the
mutation, suggesting that free radicals may play an important pathogenetic role.
5.1.3. Mitochondrial Translation Elongation Factor Tu (EF-Tu, TUFM), Malate Dehydrogenase 2
(MDH2), and Mn Superoxide Dismutase (SOD2)
Translation elongation factor Tu (EF-Tu, TUFM) promotes the GTP-dependent binding of
aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis. Marked increases (>300%)
of the amount of HNE-modified EF-Tu was detected in post-mortem homogenates of IPL from
patients with amnestic MCI, in comparison with control brains, but no activity measurements were
performed [109]. Mutations of the TUFM gene are associated with combined oxidative phosphorylation
deficiency 4 (COXPD4, MIM 610678), a disease resulting in severely decreased mitochondrial protein
synthesis and combined deficiency of mtDNA-encoded respiratory chain complex subunits, with
neonatal onset of lactic acidosis and rapidly progressive encephalopathy.
Mitochondrial malate dehydrogenase 2 (MDH2) catalyzes the last step in the Krebs cycle, i.e., the
reversible oxidation of malate to oxaloacetate. This enzyme plays a key role also in gluconeogenesis,
by reducing mitochondrial oxaloacetate to malate, which is transported into the cytosol, to be oxidized
back to oxaloacetate. Marked increases (>500%) in the levels of HNE-modified MDH2 in post-mortem
IPL homogenates from patients with EAD, in comparison with control samples, were reported in
association with a 160% increase of enzymatic activity [110]. There are no known human disease
phenotypes associated with the mutations of the MDH2 gene.
Mn superoxide dismutase (SOD2) detoxifies cells by destroying excess superoxide anion radicals.
Marginal increases in the levels of HNE-modified SOD2 were detected in the IPL of patients with
EAD, in comparison with controls. These were accompanied by a 45% activity reduction [109].
In contrast, the amount of HNE-modified SOD2 in the IPL of patients with LAD was 170% over control
values; the protein levels of this enzyme where also increased, while the enzymatic activity did not
show significant changes [121]. Variations of the SOD2 gene affect the individual susceptibility to
microvascular complications of diabetes 6 (MVCD6, MIM 612634), a combination of pathological
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conditions characterized by increased vascular permeability, tissue ischemia and angiogenesis,
developing in various tissues and organs as a consequence of diabetes mellitus, and including diabetic
retinopathy, nephropathy, and neuropathy.
5.2. Malondialdehyde-Modified Mitochondrial Proteins
Ubiquinol-Cytochrome c Reductase (Respiratory Complex III, Cytochrome B-C1) Core Protein 1
(UQCRC1), ATP Synthase (Respiratory Complex V) Beta Subunit (ATP5B), and 60-kDa Heat Shock
Protein (HSPD1, HSP60, GroEL), and Mitochondrial Glutamate Dehydrogenase 1 (GDH1)
These four enzymes will be discussed together, as all of their oxidative modifications were
reported in the same detailed study of the products generated by diverse oxidative pathways (direct
metal-catalyzed oxidation, reaction with mixed AGEs/ALEs and with LPO products) in post-mortem
brain samples from eight AD patients and five age-matched controls. In particular, N-(MDA)-lysine
adducts with UQCRC1 and ATP5B were found in AD brains at concentrations largely exceeding
(>400%) those found in control brains, while only slight increases of the N-(MDA)-lysine adducts
with HSP60 and no increases of the corresponding adducts with GDH1 were observed. No functional
characterization of the oxidized enzymes was provided [116].
Ubiquinol:ferrocytochrome c oxidoreductase (Respiratory Complex III, EC 1.10.2.2), located
within the IMM, catalyzes the second step in the electron transport chain, i.e., the transfer of electrons
from ubiquinol (reduced coenzyme Q10) to cytochrome c, coupled with proton translocation from the
mitochondrial matrix to the intermembrane space. Complex III was resolved into 11 polypeptides
by SDS-PAGE. Mutations of the UQCRC1 gene have not been reported. Instead, several mutations
in nuclear genes encoding other complex III subunits, assembly factors, and chaperones have been
described. The most severe neurodegenerative disorders, with encephalopathy and psychomotor
retardation or regression, are nuclear types 1, 2, 4, 7, 8 and 9 of mitochondrial complex III deficiency,
respectively associated with mutations of the BCS1L, TTC19, UQCRQ, UQCC2, UQCC3 and LYRM7
genes, respectively encoding mitochondrial chaperone BCS1, mitochondrial tetratricopeptide repeat
protein 19 (both required for complex III assembly), cytochrome b-c1 subunit 8, ubiquinol-cytochrome-c
reductase assembly factors 2 and 3, and LYRM7 (an assembly factor for Rieske Fe-S protein).
Mitochondrial type complex III deficiency can also be caused by mutations of the MTCYB gene,
encoding cytochrome b, the only mitochondrial-encoded subunit of complex III. Disease alleles are
associated with phenotypes of LHON (Leber’s hereditary optic neuropathy, MIM 535000), or of exercise
intolerance, isolated or in association with encephalomyopathy, cardiomyopathy, or multisystem
disorder (growth and mental retardation, epilepsy, deafness, retinitis pigmentosa).
ATP synthase beta subunit is part of the F1 fraction of the ATP synthase complex (Respiratory
Complex V, EC 3.6.3.14). The contribution of the oxidative damage of mitochondrial ATP synthase
(Respiratory Complex V) to neurodegeneration has been discussed above, in relation with the adducts
of HNE with the ATP synthase alpha subunit detected in AD. Mutations of the ATP5B gene have not
been described in association with the inherited defects of respiratory complex V.
HSP60 functions as a chaperone in mitochondrial protein import and macromolecular assembly.
It may also prevent misfolding and promote the refolding and proper assembly of unfolded
polypeptides generated under stress conditions in the mitochondrial matrix. Mutations of the HSPD1
gene are associated with spastic paraplegia 13, AD (SPG13, MIM 605280), a neurodegenerative
disorder characterized by a slow, progressive weakness and spasticity of the lower limbs, whose
rate of progression and clinical severity can vary [140]. In some forms of the disorder, urinary
incontinence may appear, or the weakness and stiffness may spread to other parts of the body. Allelic
mutations of the HSPD1 gene cause leukodystrophy, hypomyelinating, 4 (HLD4, MIM 612233), a
severe autosomal recessive, hypomyelinating leukodystrophy, characterized by infantile-onset rotary
nystagmus, progressive spastic paraplegia, neurologic regression, motor impairment, profound mental
retardation, with death occurring within the first two decades.
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Mitochondrial glutamate dehydrogenase 1 (GDH1) plays a key role in glutamine anaplerosis,
by converting L-glutamate into alpha-ketoglutarate, an important intermediate in the tricarboxylic
acid cycle. Mutations of the GDH1 gene are associated with familial hyperinsulinemic hypoglycemia
6 (HHF6, congenital hyperinsulinism, MIM 606762), the most common cause of infantile persistent
hypoglycemia, due to defective feedback regulation of insulin secretion by glucose.
5.3. Mitochondrial Proteins with Increased Content of DPNH-Reactive Groups
5.3.1. Mitochondrial Aconitate Hydratase (Aconitase 2, ACO2)
Increased contents of protein carbonyls were detected by Western blot after derivatization with
DNPH in aconitate hydratase (aconitase 2, ACO2), as well as in glial fibrillary acidic protein (GFAP),
γ-enolase and ubiquitous mitochondrial creatine kinase (CKMT1A), in a proteomic and enzymatic
analysis of human brain post-mortem samples from the striatum and cortex of eight patients with
Huntington’s disease (HD) and as many matched controls. Notably, ACO2 showed a selective, se in
protein level and a 35% decrease of enzymatic activity in the striatum, but not in the cortex of HD
patients, suggesting that the loss of activity could be a consequence both of reduced protein levels and
of inactivation by oxidative modification [129]. It had been reported previously that ACO2 activity
was decreased to 8% in HD caudate, 27% in putamen and 52% in cerebral cortex (being normal in HD
cerebellum and fibroblasts), and was more sensitive to inhibition by nitric oxide (NO), in comparison
with respiratory complexes II and III, already known to be vulnerable to it. It was hypothesized that
a self-amplifying cycle of ROS generation and aconitase inhibition, triggered by NO and resulting
in severe ATP depletion, might be critical for neuronal cell death and HD pathogenesis [141]. These
results were in keeping with those reported later in relation to AD [121] and described in 5.1.1, where
the disease phenotypes associated with the mutations of the ACO2 gene have also been described.
5.3.2. Mitochondrial Citrate Synthase (CS), Ubiquitous Creatine Kinase (CKMT1A),
Ubiquinol-Cytochrome c Reductase (Respiratory Complex III, Cytochrome B-C1) Core Protein 2
(UQCRC2), and ATP Synthase (Respiratory Complex V) Alpha Subunit 1 (ATP5A1)
These four enzymes will also be discussed together, as their oxidative modifications in HD were
reported in a single study. In a refinement of the above-cited study [129] of protein carbonylation
in the striatum of HD patients, Sorolla et al. identified 13 carbonylated, low-abundance proteins,
seven of which were involved in energy production, including three glycolytic and four mitochondrial
enzymes, namely, citrate synthase (CS), ubiquitous creatine kinase (CKMT1A), ubiquinol-cytochrome
c reductase (complex III) core protein 2 (UQCRC2) and ATP synthase alpha subunit 1 (ATP5A1) [130].
Mitochondrial CS is involved in the first step of the Krebs cycle, i.e., the synthesis of isocitrate from
oxaloacetate, which precedes the reversible isomerization of isocitrate to citrate catalyzed by ACO2.
CKMT1A catalyzes the reversible transfer of phosphate between ATP and various phosphogens,
like creatine phosphate); its isoenzymes play a central role in tissues with large, variable energy
demands, such as skeletal muscle, heart and brain. In order to determine whether oxidation might
lead to decreased function, the activities of CS, CKMT1A and ATP synthase were measured in
mitochondrial-enriched striatal homogenates from HD and control subjects. All three mitochondrial
enzymes exhibited significantly decreased activities in HD samples, compared to controls, in agreement
with the mitochondrial dysfunctions observed in HD patients [142].
There are no known disease phenotypes associated with the mutations of mitochondrial CS
and CKMT1A. The mutations of the genes encoding various subunits of ubiquinol-cytochrome
c reductase (complex III) have been described in point 5.2.2. A homozygous mutation of the
UQCRC2 gene, encoding complex III core protein 2, was reported in three patients, in association
with mitochondrial complex III deficiency nuclear type 5 (MC3DN5, MIM 615160), presenting with
neonatal-onset metabolic acidosis, hyperammonemia and hypoglycemia. The mutation, by disrupting
the hydrophobic core at the interface of the UQCRC2-containing complex, caused decreased expression
or instability of core protein 2 and decreased complex III assembly and activity [143]. Various disease
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phenotypes associated with the mutations of the alpha 1 and other subunits of mitochondrial ATP
synthase (complex V) have been reviewed in 5.1.3.
5.3.3. Antioxidant Defense Protein DJ-1 (Parkinson Protein 7, PARK7)
Antioxidant defense protein DJ-1 (Parkinson protein 7, PARK7) was found to be a target of oxidative
damage in the brains of patients with sporadic Parkinson’s disease (PD) and AD [131]. DJ-1 is a protein
deglycase that repairs glyoxal- and methylglyoxal-glycated cysteinyl, arginyl and lysyl residues in
proteins, reactivating their functions and preventing the formation of AGEs [144]. It protects cells
against hydrogen peroxide-induced death [145] and metal toxicity [146] and is required for correct
mitochondrial morphology and function, and for autophagy of dysfunctional mitochondria [147,148].
Under oxidative stress, it translocates from the cytoplasm to mitochondria and the nucleus, where it
exerts a cytoprotective effect [149]. DJ-1 was detected in tau inclusions in the brains of patients with
tauopathies [150]. Western blot analysis of tissue protein extracts from PD and AD brains separated by
2-D gel electrophoresis revealed increased levels of DJ-1, while mass spectrometric analysis showed
that DJ-1 was irreversibly oxidized by carbonylation and methionine oxidation, suggesting the possible
association of oxidative damage to DJ-1 with sporadic PD and AD [131].
Mutations of the PARK7 gene are associated with Parkinson’s disease 7 (PARK 7, MIM 606324), an
autosomal recessive, early-onset form of PD. This is a neurodegenerative disorder characterized by
resting and postural tremor, bradykinesia, muscular rigidity, anxiety and psychotic episodes. PARK7
has its onset before 40 years and exhibits slow progression and good initial response to levodopa.
5.3.4. Mitochondrial NADH-Ubiquinone Oxidoreductase (Respiratory Complex I)
Human NADH-ubiquinone reductase (Respiratory Complex I, EC 1.6.5.3) consists of at least 36
nuclear-encoded and seven mitochondrial-encoded subunits. Impaired catalytic activity of complex I
was found in multiple tissues in PD [151]. Keeney et al. performed a detailed quantitative, redox and
functional analysis of complex I and its subunits in enriched brain mitochondrial fractions from 10 PD
patients and 12 matched controls. Using complex I-specific immunocapture antibodies and anti-DNPH
antibodies, they found that complex I had in PD brains a slightly increased content of ND6 protein, a
34% lower content of 8 kDa subunit and a 47% increase of carbonyl groups in catalytic subunits. This
pattern of oxidative damage could be reproduced by incubating brain mitochondria with NADH, in the
presence of rotenone, but not by exposure to exogenous oxidants. The rate of NADH-driven electron
transfer through complex I correlated inversely with the degree of oxidative damage. The decrease in
activity of complex I in PD brain mitochondria thus correlated with misassembly and reflected the
oxidation of its subunits by reactive species from an internal source under stressful conditions [132].
Isolated complex I deficiency (MIM 252010) is the most common enzymatic defect among
the inherited disorders of oxidative phosphorylation and is highly genetically heterogeneous.
It is associated with the mutations of 23 nuclear-encoded genes, including 16 subunits and five
complex assembly genes, as well as six mitochondrial-encoded subunit genes. Its phenomics include
a wide range of disorders, from lethal neonatal disease to adult-onset neurodegeneration. Clinical
phenotypes include progressive leukodystrophy with macrocephaly, encephalopathy, hypertrophic
cardiomyopathy, myopathy, liver disease, Leigh syndrome, LHON, and some forms of Parkinson’s
disease (MIM 556500) as well.
6. Conclusions
Cancer and neurodegenerative diseases are both characterized by enhanced production of ROS,
mainly originated from mitochondrial oxidative phosphorylation. The resulting redox imbalance
is a major cause of DNA, protein, lipid damage and dysregulation of apoptotic pathways.
Its deleterious effects are readily manifested also at the subcellular level, deeply affecting mitochondria.
Increased ROS production in mitochondria of normal cells can induce carcinogenesis by altering
mitochondrial respiration, inducing mtDNA mutations and activating several of the signaling
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pathways that are critical for tumor growth and maintenance. On the other hand, in cancer cells,
increased ROS production can induce apoptosis and enhance cancer cell susceptibility to chemotherapy
and radiation therapy [151,152]. By inducing malignant cell death, ROS might thus hinder cancer
progression. Indeed, cancer therapy with pro-oxidant compounds has become a promising area of
investigation [153,154].
Furthermore, ROS can induce the generation of reactive electrophilic compounds, capable of
modifying mitochondrial proteins and altering their functions. The adducts of the products of lipid
peroxidation (LPO) with mitochondrial proteins involved in energy metabolism, ATP production,
antioxidant defense, stress responses and other vital cell functions appear to participate not only
in carcinogenesis, but also in the pathogenesis of neurodegenerative diseases, such as Alzheimer’s,
Huntington’s and Parkinson’s diseases. In several instances, the detection of oxidative modifications
of mitochondrial proteins, in the form of newly formed 2,4-DPNH-reactive carbonyl groups,
protein-bound N-(MDA)-lysine and HNE-protein adducts, was accompanied by the verification
of their functional consequences on protein activities. In the absence of functional tests, support of
the view that oxidative modification of crucial cell proteins might negatively affect mitochondrial
functions and cell viability comes from a survey of human disease phenotypes associated with the
mutations of the mitochondrial proteins targeted by LPO products in the context of neurodegeneration.
A number of antioxidants, including various plant-derived phenolic compounds, are under
investigation as chemopreventive agents, capable of maintaining or restoring cell redox balance for
the purpose of preventing cancer and neurodegeneration [155]. Notwithstanding some encouraging
results of the in vitro experiments, the use of antioxidants for treating neurodegenerative diseases has
been tested repeatedly in clinical trials, without convincing results [156,157]. The identification and
characterization of definite molecular targets of oxidative modification in mitochondria, involved
in the pathogenesis of cancer and neurodegeneration, in addition to providing a rationale for the
mitochondrial dysfunctions that have been documented in these disease conditions, may foster a
deeper understanding of the mechanisms by which oxidative stress participates in their pathogenesis,
thus inspiring more rational therapeutic strategies for the control of cellular redox imbalance and its
undesirable effects. In perspective, the identification of such targets may pave the way to the design
and experimentation of specific transcriptional modulators, protein stabilizers, allosteric modifiers
and enzymatic cofactors of the proteins in point. In due time, these advances may provide us not only
with the conceptual and analytical means that are required for more detailed molecular diagnoses,
but also with active compounds to be used in targeted molecular therapies that may be tailored to the
individual needs of patients, as the emerging concepts of personalized medicine demand.
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